Potential Using of Resveratrol and Its Derivatives in Medicine


Koc T. Y., Dogan S., KARADAYI M.

Eurasian Journal of Medicine, cilt.56, sa.2, ss.136-141, 2024 (ESCI) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 56 Sayı: 2
  • Basım Tarihi: 2024
  • Doi Numarası: 10.5152/eurasianjmed.2024.24392
  • Dergi Adı: Eurasian Journal of Medicine
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.136-141
  • Anahtar Kelimeler: Piceatannol, resveratrol, resveratrol derivatives
  • Atatürk Üniversitesi Adresli: Evet

Özet

A phytoalexin polyphenolic chemical, resveratrol, can be found in a variety of foods, including cereals, peanuts, grapes, strawberries, and raspberries. It is also known that resveratrol protects the body against cardiovascular diseases as well as various types of cancer. In addition to these health issues, resveratrol is currently the subject of research since it helps treat and prevent a number of illnesses. More clinical research is needed to validate resveratrol’s potential as a therapeutic agent, despite the plethora of in vitro and in vivo evidence to support this. When the literature data are evaluated, the fact that resveratrol has a therapeutic effect in these studies, but it is known to be subject to rapid metabolism despite its low bioavailability and oral absorption of approximately 75%, has directed the studies to resveratrol derivatives, especially piceatannol. Based on recent studies, 4 types of resveratrol derivatives were assessed in this work: hydroxylated compounds, methoxylated compounds, glycosides, and oligomers. Because of their advantageous bioactivities, methoxylated, hydroxylated, and halogenated derivatives have drawn the most interest among these classes. However, as a result of these studies, more studies should be conducted to better understand whether resveratrol derivatives can be recommended as therapeutic agents.